SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
LXEO

Lexeo Therapeutics, Inc. (LXEO)

NASDAQ: LXEO · USD
Healthcare · Biotechnology
$2.95+$0.00 (+0.00%)
 
Market cap
$244M
Insider Score
Analyst consensus
Market Cap$244.23M-67.5%
Revenue (ttm)n/a
Net Income-$105.28M
EPS-$1.13
Shares Out82.79M
PE Ration/a
Forward PE-1.99
Dividendn/a
Ex-Dividend Daten/a
Volume1,164,487
Open$2.93
Previous Close$2.95
Day's Range$2.87 - $3.21
52-Week Range$2.55 - $10.99
Beta1.65
AnalystsStrong Buy
Price Target$25.11(+751.22%)
Earnings DateNov 16, 2026

About LXEO

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Address
345 Park Avenue South, New York, NY, 10010, United States
Market Cap
244 million
Employees
68
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$738.69K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $15.00 (+406.8%)

2 firms rating LXEO in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
+0.00%
5 Days
+1.37%
1 Month
-1.67%
6 Months
-43.59%
1 Year
-67.55%

$LXEO stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in LXEO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LXEO's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LXEO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New LXEO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LXEO from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from LXEO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
78

News check: Strong positive clinical trial data with 80% reduction in cardiac episodes, analyst upgrade, and regulatory progress indicate bullish outlook for LX2020.

Recent Insider Activity

Buys
0
Sells
15
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.52%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.16%
KOMPState Street SPDR S&P Kensho New Economies Composite ETF0.07%
IWCiShares Micro-Cap ETF0.05%
XBIState Street SPDR S&P Biotech ETF0.05%
FSEVFidelity Enhanced Small Cap Value ETF0.03%
IBBQInvesco Nasdaq Biotechnology ETF0.02%
IBBiShares Biotechnology ETF0.01%
BIBProShares Ultra Nasdaq Biotechnology0.01%
PWSPacer WealthShield ETF0.01%
LABUDirexion Daily S&P Biotech Bull 3X Shares0.01%

Weight is the stock’s share of each fund’s holdings.